When Medtronic put Sextant on the market at the start of the 2000s, percutaneous pedicle screw fixation looked like the obvious endpoint for lumbar surgery: the same construct, a fraction of the soft-tissue damage. Nearly a quarter-century later, that endpoint has only partly arrived. MIS spine has been one of the most promising stories in the implant market for years. The technology is better, and the clinical argument is strong. And yet, in many operating rooms, the change has been slower than expected. That says something important: the challenge is no longer just about the implants or the technique. It is about how spine surgery is actually adopted in real life — how hospitals buy, how surgeons learn, how procedures are reimbursed, and how teams work under pressure every day.
A healthy growth story sitting inside a larger one
The numbers tell a positive, but still measured, story. MIS spinal implants are growing at a healthy mid-single-digit pace, but they remain part of a much larger spine market. According to iData Research, the global MIS spinal implant market was around $4 billion in 2024 and could move toward $6 billion by 2031. That compares with a total spine and VCF implant market of roughly $21 billion.
In simple terms, MIS represents about one fifth of implant revenue today. It is growing faster than the broader category, but it is still far from replacing open surgery as the dominant business in spine.
Beyond that, precision collapses. Published “MIS spine” market sizes run from under $1.5 billion to $8 billion depending on what each firm counts — instruments only, implants, full procedure economics, endoscopy in or out. That dispersion is itself the finding: there is no settled definition of this market, which makes any single headline figure a negotiating position rather than a fact. Treat the round numbers as direction of travel, not measurement.
The procedure-level picture is murkier still. A clean, nationally representative share of lumbar fusions performed minimally invasively does not exist in the public literature. Registries capture technique inconsistently, and “MIS” stretches from a tubular microdiscectomy to a full percutaneous multilevel construct. The least-bad proxy is revenue: SNS Insider estimated open approaches still held roughly 55% of the spinal implant market in 2025, with MIS near 45% and growing faster. That should be read as directional, and as revenue share of implants — not as the proportion of lumbar operations done percutaneously, which is almost certainly lower and which nobody can state with confidence.
Why a settled clinical case hasn’t produced a default
On the metrics surgeons argue about, MIS largely won years ago. Meta-analyses and large matched series consistently show less blood loss, shorter stays, lower transfusion and infection rates, and fusion rates north of 90% — comparable to open. If clinical evidence drove adoption on its own, the question would be closed. It isn’t, for reasons that are structural rather than clinical.
The first is the learning curve. Percutaneous technique demands fluoroscopic, non-visual screw placement and a different motor skill set; the literature has flagged the steep curve since Sextant’s launch, and it remains the single most cited reason adoption stalled in the first decade.
The second is radiation. The same studies that favor MIS on recovery also show significantly higher intraoperative imaging exposure for surgeon and patient — a real occupational cost that navigation only partly offsets.
The third is capital and economics. MIS leans on navigation, robotics, expandable cages and specialized instruments. Pedicle-screw misplacement rates fall from 15–20% freehand to 2–6% with navigation, but that accuracy is bought with equipment, OR time and training that a community hospital or distributor cannot always justify. For a busy surgeon, an open fusion that takes less time and no capital stack can be the rational choice, not the lazy one.
The fourth is indication ceiling. MIS is strongest in degenerative, single- and two-level work. Complex deformity, revision and high-grade reduction still pull toward open exposure. A technique that cannot address the hardest cases will not become universal by definition.
What this means for spine companies
For executives and investors, the read is that MIS is a share-shift and premium-mix story, not a replacement story. The category grows by converting suitable degenerative cases and by pricing enabling technology — navigation, robotics, endoscopy — into the procedure, not by retiring open surgery. The fastest-growing sub-segments (lateral and oblique approaches, endoscopic fusion) are also the most capital- and training-intensive, which concentrates advantage with players who can sell a system, not a screw.
That has distribution consequences. The value migrates from the implant toward the platform and the service wrapped around it, which squeezes commodity percutaneous-screw suppliers and rewards whoever owns the enabling technology and the surgeon relationship. Outpatient and ASC migration reinforces this: MIS is the natural fit for same-day spine, but the positioning, navigation and reimbursement friction that come with it are exactly what slows the conversion.
Will technology break the logjam? Robotics and improved navigation directly attack two barriers — the learning curve and radiation — and are the most plausible accelerants. But they do nothing about the indication ceiling or the capital problem, and arguably worsen the latter. The likeliest path is continued steady gain in share, not an inflection.
More than 100 systems in the market
Access the complete list of more than 100 MIS and percutaneous spine systems here: https://thespinemarketgroup.com/category/mis/
There is another reason why MIS spine looks more mature on paper than it sometimes feels in the operating room: the market is crowded. Today, there are well over 100 systems that can be described, in one way or another, as MIS or percutaneous spine platforms. Some are full procedural systems. Others are essentially pedicle screw sets adapted for percutaneous use. Some are tied to navigation, robotics, expandable cages or specific access techniques. This abundance creates choice, but also fragmentation. For hospitals and surgeons, the question is no longer whether MIS technology exists. It clearly does. The harder question is which system is simple enough, reproducible enough and supported well enough to become part of daily practice. In that sense, the next phase of MIS will probably be less about adding more systems to the market and more about proving which platforms can actually change behavior in the OR.
###
Legal Disclaimer:
Content published on SPINEMarketGroup (thespinemarketgroup.com) is provided for informational purposes only and on an “as is” basis, without warranties of any kind. We do not guarantee the accuracy, completeness, legality, or reliability of any information, images, videos, links, or third-party materials featured on the site. Any views or claims expressed in contributed content or press releases belong to their respective authors or sources. For copyright concerns, factual corrections, or content-related complaints, please contact us directly for review.